Serina Therapeutics director receives 15,250 stock options
Serina Therapeutics, Inc. director Marshall Richard Peter reported receiving a grant of stock options covering 15,250 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Serina Therapeutics, Inc. director Marshall Richard Peter reported receiving a grant of stock options covering 15,250 shares of common stock. The options have an exercise price of $1.98 per share and expire on June 17, 2036.
According to the filing, the options vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to his continued service with the company. Following this grant, he holds 15,250 stock options directly from this award.
Insider Trade Summary
Grant/Award: 15,250 shares
Grant/Award
1 txn
Insider
Marshall Richard Peter
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,250 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 15,250 contracts (Direct)
Footnotes (1)
- F1. The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Key Figures
Options granted: 15,250 options
Exercise price: $1.98 per share
Expiration date: June 17, 2036
+1 more
4 metrics
Options granted
15,250 options
Grant to director on June 17, 2026
Exercise price
$1.98 per share
Stock option strike price
Expiration date
June 17, 2036
Option term for this grant
Underlying shares
15,250 shares
Common stock underlying granted options
Key Terms
Stock Option (right to buy), exercise price, expiration date, Annual Meeting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "1.9800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-17T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting financial
"the day before the next Annual Meeting or (ii) the one-year anniversary"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
grant date financial
"the one-year anniversary of the grant date, subject to the Reporting Person's continued service"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Serina Therapeutics (SER) director Marshall Richard Peter report on this Form 4?
He reported a grant of stock options covering 15,250 shares of Serina Therapeutics common stock. The options were awarded at an exercise price of $1.98 per share and represent compensation rather than an open-market purchase or sale of existing shares.
What are the key terms of the Serina Therapeutics (SER) stock options granted to Marshall Richard Peter?
The grant covers 15,250 options at $1.98 per share, expiring on June 17, 2036. These options give him the right to buy Serina Therapeutics common stock at that price if and when they vest and are exercised.
When do Marshall Richard Peter’s Serina Therapeutics (SER) stock options vest?
The options vest based on time and service, on the earlier of the day before the next Annual Meeting or the one-year anniversary of the June 17, 2026 grant. Vesting is conditioned on his continued service with the company.
Is this Serina Therapeutics (SER) Form 4 a stock purchase or sale by the director?
No, it reflects a compensation-related stock option grant, not an open-market trade. The options were granted at an exercise price of $1.98 and involve no cash paid or received until any future exercise of the options.
How many Serina Therapeutics (SER) stock options does Marshall Richard Peter hold after this grant?
After this reported grant, he holds 15,250 stock options from this award. These options relate to 15,250 underlying shares of common stock and will remain exercisable until their June 17, 2036 expiration, subject to vesting conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates